Obexelimab is under clinical development by Zenas BioPharma (USA) and currently in Phase III for Immunoglobulin G4-Related Disease (IgG4-RD). According to GlobalData, Phase III drugs for Immunoglobulin G4-Related Disease (IgG4-RD) does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Obexelimab LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Obexelimab overview

Obexelimab (XmAb-5871) is under development for the treatment and prevention of IgG4-related disease (IgG4-RD), a fibro-inflammatory autoimmune disorder, autoimmune hemolytic anemia and unspecified indication. It is administered by intravenous, subcutaneous, parenteral and subdermal routes. It is a humanized monoclonal antibody that targets the antigen CD19 and co-engages CD32b (Fc gammaRIIb). The drug candidate is developed based on XmAb technology. It was also under development for systemic lupus erythematosus and moderate to severe rheumatoid arthritis. 

Zenas BioPharma (USA) overview

Zenas BioPharma (USA) (Zenas) is a biopharmaceutical company. The company focuses on a rapidly advancing portfolio of innovative therapeutics. Its product pipeline includes Obexelimab (XmAb5871), ZB002, ZB004, ZB001 (IV)3, ZB011 (SC)3, and ZB0054. The company’s Obexelimab demonstrated inhibition of B-cell function without depleting the cells and generated an encouraging treatment effect in patients with multiple autoimmune diseases and IgG4-related disease (IgG4-RD); ZB001 is same as insulin-like growth factor-1 receptor (IGF1R) monoclonal antibody (mAb) which is used in treatment of thyroid eye disease (TED); ZB002 used in anti-TNFa therapies; and ZB004 used in CTLA4-Ig fusion protein therapies. It operated across the US. Zenas is headquartered in Waltham, Massachusetts, the US.

For a complete picture of Obexelimab’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.